CN113271938A - Tyk2抑制剂和其用途 - Google Patents

Tyk2抑制剂和其用途 Download PDF

Info

Publication number
CN113271938A
CN113271938A CN201980087661.3A CN201980087661A CN113271938A CN 113271938 A CN113271938 A CN 113271938A CN 201980087661 A CN201980087661 A CN 201980087661A CN 113271938 A CN113271938 A CN 113271938A
Authority
CN
China
Prior art keywords
compound
nitrogen
sulfur
oxygen
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980087661.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·葛林伍德
C·E·玛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Nimbus Lakshmi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Lakshmi Inc filed Critical Nimbus Lakshmi Inc
Publication of CN113271938A publication Critical patent/CN113271938A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980087661.3A 2018-11-30 2019-11-27 Tyk2抑制剂和其用途 Pending CN113271938A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773620P 2018-11-30 2018-11-30
US62/773,620 2018-11-30
PCT/US2019/063510 WO2020112937A1 (en) 2018-11-30 2019-11-27 Tyk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN113271938A true CN113271938A (zh) 2021-08-17

Family

ID=70848642

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980087661.3A Pending CN113271938A (zh) 2018-11-30 2019-11-27 Tyk2抑制剂和其用途

Country Status (8)

Country Link
US (2) US11053241B2 (enExample)
EP (1) EP3886843A4 (enExample)
JP (2) JP7530360B2 (enExample)
CN (1) CN113271938A (enExample)
AU (1) AU2019389025B2 (enExample)
CA (1) CA3120866A1 (enExample)
IL (1) IL283409A (enExample)
WO (1) WO2020112937A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117342955A (zh) * 2023-10-08 2024-01-05 盐城师范学院 一种制备4’-甲基-联苯-2-胺的方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
CA3120866A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
JP2024501507A (ja) * 2020-12-25 2024-01-12 スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド ケトヘキソキナーゼ阻害剤及びその用途
WO2022193499A1 (en) 2021-03-16 2022-09-22 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
TW202425965A (zh) * 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
CN115974751A (zh) * 2022-12-13 2023-04-18 山东能源集团新材料有限公司 一种吡拉西坦制备方法及系统
IL321581A (en) * 2022-12-22 2025-08-01 Protekt Therapeutics Ltd Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors
WO2025010294A2 (en) * 2023-07-03 2025-01-09 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as tyk2 inhibitors
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors
US11878978B1 (en) 2023-09-06 2024-01-23 King Faisal University Pyrrolo[2,3-c]quinoline compounds as CK2 inhibitors
WO2025222103A1 (en) * 2024-04-19 2025-10-23 Raythera, Inc. Stat6 modulators and methods of uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180037570A1 (en) * 2016-08-08 2018-02-08 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2018071794A1 (en) * 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018089695A1 (en) * 2016-11-11 2018-05-17 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
PL338575A1 (en) 1997-08-05 2000-11-06 Pfizer Prod Inc 4-aminopyrrole(3,2-d)pyrimidines as antagonists of neuropeptide y receptor
CN1195755C (zh) 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DE60325740D1 (de) 2002-08-14 2009-02-26 Silence Therapeutics Ag Verwendung von protein-kinase-n-beta
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
SI1644363T1 (sl) 2003-05-30 2012-07-31 Gemin X Pharmaceuticals Canada Inc Triheterociklične spojine sestavki in postopki za zdravljenje raka
EP2371835A1 (en) 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
ES2873875T3 (es) 2004-05-13 2021-11-04 Icos Corp Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
ATE412651T1 (de) * 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
EP1787991B2 (en) 2004-07-28 2020-06-24 Takeda Pharmaceutical Company Limited PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CN101282948A (zh) 2005-10-07 2008-10-08 埃克塞里艾克西斯公司 N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2014074661A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES
TWI620737B (zh) 2012-11-08 2018-04-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
WO2015089143A1 (en) 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
CA2940666C (en) 2014-02-28 2022-08-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CR20160512A (es) 2014-05-01 2016-12-21 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7
CA3120866A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180037570A1 (en) * 2016-08-08 2018-02-08 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2018071794A1 (en) * 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2018089695A1 (en) * 2016-11-11 2018-05-17 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117342955A (zh) * 2023-10-08 2024-01-05 盐城师范学院 一种制备4’-甲基-联苯-2-胺的方法

Also Published As

Publication number Publication date
JP7530360B2 (ja) 2024-08-07
AU2019389025B2 (en) 2025-07-24
EP3886843A1 (en) 2021-10-06
EP3886843A4 (en) 2022-08-31
JP2022509260A (ja) 2022-01-20
US11834449B2 (en) 2023-12-05
IL283409A (en) 2021-07-29
JP2024160253A (ja) 2024-11-13
US20220106306A1 (en) 2022-04-07
US20200172540A1 (en) 2020-06-04
CA3120866A1 (en) 2020-06-04
AU2019389025A1 (en) 2021-06-17
WO2020112937A1 (en) 2020-06-04
US11053241B2 (en) 2021-07-06

Similar Documents

Publication Publication Date Title
AU2019389025B2 (en) TYK2 inhibitors and uses thereof
CN109952303B (zh) Tyk2抑制剂及其用途
US10968236B2 (en) TYK2 inhibitors and uses thereof
JP7699052B2 (ja) Ｔｙｋ２阻害剤およびその使用
CN113271940A (zh) Tyk2抑制剂和其用途
TW201920178A (zh) Tyk2抑制劑及其用途
HK40055822A (en) Tyk2 inhibitors and uses thereof
HK40055822B (en) Tyk2 inhibitors and uses thereof
HK40009936A (en) Tyk2 inhibitors and uses thereof
HK40009936B (en) Tyk2 inhibitors and uses thereof
HK1248690B (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20231129

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts

Applicant before: NIMBUS LAKSHMI, Inc.

TA01 Transfer of patent application right